ClinicalTrials.gg
RecruitingNCT06463483AIDkidneyUpdated Jan 8, 2026

Automated Insulin Delivery in Adults With Advanced Kidney Disease

An interventional study of Medtronic 780G System and Continuous Glucose Monitoring in Chronic Kidney Diseases and Diabetes Mellitus, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Imperial College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Renal Insufficiency, Chronic with a site in United Kingdom — 32 open to participants now, 50 under way, 17 of them phase 3. Renal Insufficiency, Chronic · United Kingdom.

Planned enrollment
146th of 159
12 · median 139
Started
2025
with 10 others
No phase
31 of 230
5 open now
Primary completion
2026-12
later than 13 of 49 live
Registered
204th of 230
by date
Lead sponsor
6 of 230
Imperial College London

Among the 230 studies in Renal Insufficiency, Chronic with a site in United Kingdom, this one is the 146th largest by planned enrollment of the 159 interventional ones that give a count, is one of 11 that started in 2025, is one of 31 with no phase, reaches primary completion later than 13 of the 49 other live ones, and was the 204th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

32 of the 230 studies in Renal Insufficiency, Chronic with a site in United Kingdom are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Renal Insufficiency, Chronic with a site in United Kingdom, or all of them as a file.
02

Study summary

Diabetes is the leading cause of kidney failure in the UK. Many people with diabetes and advanced kidney failure inject themselves with insulin and do finger-prick blood glucose tests. Managing diabetes in people with advanced kidney disease is hard, with fluctuating glucose levels and an increased risk of unsafe low glucose levels.

There are currently continuous glucose monitors (CGM), which allow people to monitor glucose without painful fingerprick tests. CGM can be combined with insulin pumps to create automated insulin delivery systems (AID) that deliver insulin automatically to control glucose. AID systems are currently used in people with type 1 diabetes, but they are not used in people with type 2 diabetes. There is little information on how these systems might help people with diabetes and advanced kidney failure and on dialysis.

This study will investigate whether automated insulin delivery can improve glucose levels and quality of life in people with diabetes treated with more than one insulin injection with advanced kidney failure and/or undergoing regular dialysis treatment. This study will be a feasibility study conducted in a single centre (Imperial College, London) and be of a cross-over design. The study will aim to complete 12 people. Participants will wear a glucose sensor at the start. In random order, half will start AID followed by the usual treatment, while the other half will start the usual treatment followed by AID treatment. The duration of each treatment stage is eight weeks. The study will last about 22 weeks for each participant. Investigators will compare the glucose levels in the AID group with the usual care group to see if there is a difference. Questionnaires and interviews will help us understand participants' experiences. Investigators will carefully monitor the safety of participants.

Read the detailed description

This will be a single-centre, prospective, open-label, two-stage, randomized crossover study comparing automated subcutaneous insulin delivery (AID), also known as Hybrid Closed Loop (HCL) therapy using the 780G system with usual insulin therapy plus continuous glucose monitoring (CGM) in people with type 1 and type 2 diabetes complicated by advanced renal disease and managed with insulin. The study will be conducted at Imperial College Healthcare NHS Trust.

Duration of each treatment arm is 8 weeks

03

Conditions studied

  • Chronic Kidney Diseases
  • Diabetes Mellitus

Keywords

  • Diabetes
  • Automated Insulin Delivery
  • Dialysis
  • Chronic Kidney Diseases
  • Insulin
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age 18-70 years inclusive
  • 2. Type 1 diabetes of at least 1-year duration or insulin-requiring type 2 diabetes managed with multiple daily injections (MDI [ie separate rapid-acting and basal insulin injections]) or insulin pump therapy (CSII)
  • 3. The \<10.5% (\<91 mmol/mol)
  • 4. The total daily dose of insulin \<200Units
  • 5. The participant is willing and able to implement the study requirements.
  • 6. Participant has advanced renal disease (Group A: Stage 3b or greater renal failure ( \<45millilitres/minute/1.73m2); Group B: ESKD requiring peritoneal dialysis; Group C: ESKD requiring haemodialysis
  • 7. Participants (and carer where applicable) should be able to speak and understand English sufficiently for safe study conduct
  • 8. The participant has internet or smartphone access, enabling upload of the 780G system data to cloud-based software

Exclusion criteria

Exclusion Criteria:

  • 1. The participant is already using an AID system
  • 2. The participant is treated with sulphonylureas (SGLT2 inhibitors, metformin, and GLP1 analogues may be used within regulatory guidelines) in pre-dialysis participants (Group A). In Groups B \& C, noninsulin glucose-lowering therapies are not permitted, with the exception of GLP1 agonists used in preparation for transplantation
  • 3. The participant has a recent history of diabetic ketoacidosis (\<6 months)
  • 4. The use of systemic therapy within the past four weeks (stable doses of steroids for >8 weeks permitted)
  • 5. The participant has significant cognitive impairment or major psychiatric history affecting safe study conduct
  • 6. Known significant allergy to tape/ adhesives
  • 7. Women who are pregnant or planning pregnancy
  • 8. The participant has an active major life-threatening illness limiting the participants to \<6 months
  • 9. The participant is on hydroxyurea treatment or taking regular / daily paracetamol treatment (sensor interference)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Automated insulin delivery using Medtronic 780G System

    Device: Medtronic 780G System

  • Other
    Usual care plus continuous glucose monitoring

    Device: Continuous Glucose Monitoring

Interventions

  • DeviceMedtronic 780G System

    Automated insulin delivery using Medtronic 780G system

  • DeviceContinuous Glucose Monitoring

    Usual care with continuous glucose monitoring

06

What researchers measure

Primary outcomes

  1. Percent time in sensor glucose target range (3.9-10.0 mmol/L)

    Percent time in sensor glucose target range (3.9-10.0 mmol/L) with Automated Insulin Delivery (AID) versus Usual Care measured during the final 3 weeks of each study stage.

    Time frame: 3 weeks

Secondary outcomes

  1. Percent time in sensor glucose target range (<3.0 mmol/L)

    Percent time in sensor glucose target range (\<3.0 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage

    Time frame: 3 weeks

  2. Percent time in sensor glucose target range (<3.9 mmol/L)

    Percent time in sensor glucose target range (\<3.9 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage

    Time frame: 3 weeks

  3. Percent time in sensor glucose target range (>10 mmol/L)

    Percent time in sensor glucose target range (\<10 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage

    Time frame: 3 weeks

  4. Percent time in sensor glucose target range (<2.8 mmol/L)

    Percent time in sensor glucose target range (\<2.8 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage

    Time frame: 3 weeks

  5. Percent time in sensor glucose target range (<3.3 mmol/L)

    Percent time in sensor glucose target range (\<3.3 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage

    Time frame: 3 weeks

  6. Percent time in sensor glucose target range (>13.9 mmol/L)

    Percent time in sensor glucose target range (\<13.9 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage

    Time frame: 3 weeks

  7. Percent time in sensor glucose target range (>16.7 mmol/L)

    Percent time in sensor glucose target range (\<16.7 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage

    Time frame: 3 weeks

  8. Percent time in sensor glucose target range (3.9-7.8 mmol/L)

    Percent time in sensor glucose target range (3.9-7.8 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage

    Time frame: 3 weeks

  9. Mean sensor glucose

    Mean sensor glucose with AID versus Usual Care, measured during the final 3 weeks of each study stage

    Time frame: 3 weeks

  10. Standard deviation and coefficient of variation of sensor glucose

    Standard deviation and coefficient of variation of sensor glucose with AID versus Usual Care, measured during the final 3 weeks of each study stage

    Time frame: 3 weeks

  11. The Diabetes Treatment Satisfaction Questionnaire status

    The Diabetes Treatment Satisfaction Questionnaire status with AID versus Usual Care

    Time frame: 8 weeks

  12. Hypoglycaemia Fear Survey

    Hypoglycaemia Fear Survey with AID versus Usual Care

    Time frame: 8 weeks

  13. EQ-5D-5L

    EQ-5D-5L with AID versus Usual Care

    Time frame: 8 weeks

  14. Episodes of CGM time in <3.0mmol/L range lasting >15minutes

    Episodes of CGM time in \<3.0mmol/L range lasting \>15minutes with AID versus Usual Care

    Time frame: 3 weeks

  15. Number of hospital admissions with diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycaemia

    Number of hospital admissions with diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycaemia with AID versus Usual Care

    Time frame: 8 weeks

  16. Number of hospitalised and non-hospitalised patients with severe hypoglycaemia

    Number of hospitalised and non-hospitalised patients with severe hypoglycaemia with AID versus Usual Care

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Boughton CK, Tripyla A, Hartnell S, Daly A, Herzig D, Wilinska ME, Czerlau C, Fry A, Bally L, Hovorka R. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med. 2021 Aug;27(8):1471-1476. doi: 10.1038/s41591-021-01453-z. Epub 2021 Aug 4. PubMed 34349267 ↗
  • Bally L, Gubler P, Thabit H, Hartnell S, Ruan Y, Wilinska ME, Evans ML, Semmo M, Vogt B, Coll AP, Stettler C, Hovorka R. Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney Int. 2019 Sep;96(3):593-596. doi: 10.1016/j.kint.2019.03.006. Epub 2019 Mar 20. PubMed 31133457 ↗
  • Lu JC, Lee P, Ierino F, MacIsaac RJ, Ekinci E, O'Neal D. Challenges of Glycemic Control in People With Diabetes and Advanced Kidney Disease and the Potential of Automated Insulin Delivery. J Diabetes Sci Technol. 2024 Nov;18(6):1500-1508. doi: 10.1177/19322968231174040. Epub 2023 May 10. PubMed 37162092 ↗

Individual participant data

Plan to share: No — No plans to share IPD

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 13 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 17, 2024
StartActual
Nov 1, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Feb 1, 2027
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06463483
Responsible party
Sponsor
First posted
Jun 17, 2024
Start date
Nov 1, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Jan 8, 2026

Study contacts

Lalantha Leelarathna, FRCP PhD
Contact
e.leelarathna@imperial.ac.uk
+447984477771
Nick Oliver, FRCP PhD
Contact
nick.oliver@imperial.ac.uk

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion